CCA
BPMC

Catalyst Capital Advisors’s Blueprint Medicines BPMC Stock Holding History

Catalyst Capital Advisors’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-35
Closed -$3K – 493
2018
Q1 		$3K Buy
+35
New +$3.02K ﹤0.01% 440

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Catalyst Capital Advisors's BPMC Position: Q2 2018 in Review

Catalyst Capital Advisors sold out of Blueprint Medicines (BPMC) in Q2 2018, closing a stake of 35 shares — an estimated $3K sold.

Catalyst Capital Advisors first reported a position in BPMC in Q1 2018 and held it in 1 quarter. The position peaked at $3K in Q1 2018. 181 funds tracked by Wall St. Rank hold BPMC as of Q2 2018.

  • Catalyst Capital Advisors reported no remaining Blueprint Medicines position as of Q2 2018 after selling out during the quarter.
  • Catalyst Capital Advisors sold 35 Blueprint Medicines shares in Q2 2018, an estimated $3K.
  • Catalyst Capital Advisors first reported a position in Blueprint Medicines in Q1 2018 and held it in 1 quarter.
  • Catalyst Capital Advisors's Blueprint Medicines position peaked at $3K in Q1 2018.
  • 181 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2018.

Based on Catalyst Capital Advisors's 13F filing for Q2 2018, filed 7 Aug 2018.